List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1004900/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The PRECISE-DAPT score and 5-year outcomes after percutaneous coronary intervention: a large-scale, real-world study from China. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 812-820.	4.0	6
2	High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort. Cardiovascular Diabetology, 2022, 21, 46.	6.8	27
3	Association of <i>NPC1L1</i> and <i>HMGCR</i> Gene Polymorphisms with Major Adverse Cardiac and Cerebrovascular Events in Patients with Three-Vessel Disease. Human Gene Therapy, 2021, 32, 581-588.	2.7	5
4	Body mass index and mortality in patients with severe coronary artery diseases: A cohort study from China. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 448-454.	2.6	7
5	Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3Âyears study from China. Cardiovascular Diabetology, 2021, 20, 16.	6.8	7
6	Long-Term Outcomes of Single-Vessel Percutaneous Coronary Intervention on Culprit Vessel vs. Multivessel Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Multivessel Coronary Artery Disease. Circulation Journal, 2021, 85, 185-193.	1.6	1
7	Abstract PS1-31: Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapy. , 2021, , .		0
8	Scanning Electron Microscopic Assessment of Stent Coating Integrity in Jailed Wire Technique for Bifurcation Treatment. Journal of Interventional Cardiology, 2021, 2021, 1-5.	1.2	2
9	Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study. Cardiovascular Diabetology, 2021, 20, 143.	6.8	22
10	5-Year Clinical Outcomes of Successful Recanalisation for Coronary Chronic Total Occlusions in Patients With or Without Type 2 Diabetes Mellitus. Frontiers in Cardiovascular Medicine, 2021, 8, 691641.	2.4	2
11	Effects of metabolic syndrome on onset age and long-term outcomes in patients with acute coronary syndrome. World Journal of Emergency Medicine, 2021, 12, 36.	1.0	6
12	Similar Inflammatory Biomarkers Reflect Different Platelet Reactivity in Percutaneous Coronary Intervention Patients Treated With Clopidogrel: A Large-Sample Study From China. Frontiers in Cardiovascular Medicine, 2021, 8, 736466.	2.4	6
13	Does Prior Stroke Predict Long-Term Recurrent Stroke After Percutaneous Coronary Intervention? Five-Year Results From a Large Cohort Study. Frontiers in Neurology, 2021, 12, 740136.	2.4	2
14	Effect of NPC1L1 and HMGCR Genetic Variants With Premature Triple-Vessel Coronary Disease. Frontiers in Cardiovascular Medicine, 2021, 8, 704501.	2.4	5
15	Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Global Heart, 2021, 16, 89.	2.3	2
16	Lipoprotein(a) levels are associated with coronary severity but not with outcomes in Chinese patients underwent percutaneous coronary intervention. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 265-273.	2.6	17
17	Impact of Lipoprotein(a) on Long-Term (Mean 6.2 Years) Outcomes in Patients With Three-Vessel Coronary Artery Disease. American Journal of Cardiology, 2020, 125, 528-533.	1.6	8
18	Clinical characteristics of early and late drug-eluting stent in-stent restenosis and mid-term prognosis after repeated percutaneous coronary intervention. Chinese Medical Journal, 2020, 133, 2674-2681.	2.3	3

#	Article	IF	CITATIONS
19	Platelet microRNA-15b protects against high platelet reactivity in patients undergoing percutaneous coronary intervention through Bcl-2-mediated platelet apoptosis. Annals of Translational Medicine, 2020, 8, 364-364.	1.7	6
20	Clinical Application and Feasibility of MRI-Guided Breast Biopsy of Breast Minimal Lesions in Chinese Population. Frontiers in Oncology, 2020, 10, 257.	2.8	2
21	D-dimer as a thrombus biomarker for predicting 2-year mortality after percutaneous coronary intervention. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232090430.	2.5	18
22	Recent Progress for the Techniques of MRI-Guided Breast Interventions and their applications on Surgical Strategy. Journal of Cancer, 2020, 11, 4671-4682.	2.5	6
23	Prognostic value of the GRACE discharge score for predicting the mortality of patients with stable coronary artery disease who underwent percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2020, 95, 550-557.	1.7	2
24	Association of <i>β</i> -Blocker Therapy at Discharge with Clinical Outcomes after Acute Coronary Syndrome in Patients without Heart Failure. Cardiovascular Therapeutics, 2020, 2020, 1-10.	2.5	5
25	Evidence in Guidelines for Treatment of Coronary Artery Disease. Advances in Experimental Medicine and Biology, 2020, 1177, 37-73.	1.6	52
26	Contrast Induced Nephropathy and 2-Year Outcomes of Iso-Osmolar Compared with Low-Osmolar Contrast Media after Elective Percutaneous Coronary Intervention. Korean Circulation Journal, 2020, 51, 174.	1.9	9
27	Prognostic Significance of In-hospital Acquired Thrombocytopenia in Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. American Journal of the Medical Sciences, 2019, 358, 19-25.	1.1	3
28	Prognostic Value of the PARIS Thrombotic Risk Score for 2-Year Mortality After Percutaneous Coronary Intervention. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961985363.	1.7	3
29	Implications of N-terminal pro-B-type natriuretic peptide in patients with three-vessel disease. European Heart Journal, 2019, 40, 3397-3405.	2.2	39
30	Association of Baseline Smoking Status with Long-Term Prognosis in Patients Who Underwent Percutaneous Coronary Intervention: Large Single-Center Data. Journal of Interventional Cardiology, 2019, 2019, 1-9.	1.2	4
31	Generalized linear model (GLM) analysis: Multivariables of microcalcification specimens obtained via X-ray guided by stereotactic wire localization biopsy. Journal of X-Ray Science and Technology, 2019, 27, 493-502.	1.0	0
32	Nomogram to Assist in Surgical Plan for Hepatocellular Carcinoma: a Prediction Model for Microvascular Invasion. Journal of Gastrointestinal Surgery, 2019, 23, 2372-2382.	1.7	34
33	Prognostic Value of Plasma Big Endothelin-1 Level among Patients with Three-Vessel Disease: A Cohort Study. Journal of Atherosclerosis and Thrombosis, 2019, 26, 959-969.	2.0	9
34	Predictive value of in-hospital white blood cell count in Chinese patients with triple-vessel coronary disease. European Journal of Preventive Cardiology, 2019, 26, 872-882.	1.8	31
35	Evaluation of a novel score for predicting 2-year outcomes in patients with acute coronary syndrome after percutaneous coronary intervention. Journal of the Chinese Medical Association, 2019, 82, 616-622.	1.4	5
36	High high-sensitivity C-reactive protein/BMI ratio predicts future adverse outcomes in patients with acute coronary syndrome. Coronary Artery Disease, 2019, 30, 448-454.	0.7	3

#	Article	IF	CITATIONS
37	Relationship between fibrinogen levels and cardiovascular events in patients receiving percutaneous coronary intervention. Chinese Medical Journal, 2019, 132, 914-921.	2.3	9
38	Effect of prior stroke on longâ€term outcomes of percutaneous coronary interventions in Chinese patients: A large singleâ€center study. Catheterization and Cardiovascular Interventions, 2019, 93, E75-E80.	1.7	3
39	Impact of baseline estimated glomerular filtration rate on inhospital outcomes of patients with STâ€elevation myocardial infarction undergoing primary percutaneous coronary intervention: A China acute myocardial infarction registry study. Catheterization and Cardiovascular Interventions, 2019, 93, 793-799.	1.7	4
40	Implications of Hyperuricemia in Severe Coronary Artery Disease. American Journal of Cardiology, 2019, 123, 558-564.	1.6	14
41	Two-year prognostic value of mean platelet volume in patients with diabetes and stable coronary artery disease undergoing elective percutaneous coronary intervention. Cardiology Journal, 2019, 26, 138-146.	1.2	10
42	Predictive value of neutrophil to lymphocyte ratio in longâ€ŧerm outcomes of left main and/or threeâ€øessel disease in patients with acute myocardial infarction. Catheterization and Cardiovascular Interventions, 2018, 91, 551-557.	1.7	30
43	Sexâ€based differences in bleeding and longâ€ŧerm adverse events after percutaneous coronary intervention in older patients with coronary artery disease. Journal of Interventional Cardiology, 2018, 31, 345-352.	1.2	4
	Effect of sex difference in clinical presentation (stable coronary artery disease vs unstable angina) Tj ETQq0 0 0	rgBT /Ove	rlock 10 Tf 50
44	outcomes in patients undergoing percutaneous coronary intervention. Journal of Interventional Cardiology, 2018, 31, 5-14.	1.2	17
45	Comparison of Efficacy and Safety between First- and Second-Generation Drug-Eluting Stents in Patients with Acute Coronary Syndrome. Chinese Medical Journal, 2018, 131, 1397-1405.	2.3	Ο
46	Impact of Residual SYNTAX Score and Its Derived Indexes on Clinical Outcomes after Percutaneous Coronary Intervention. Chinese Medical Journal, 2018, 131, 1390-1396.	2.3	3
47	Validation of Predictive Value of Patterns of Nonadherence to Antiplatelet Regimen in Stented Patients Thrombotic Risk Score in Chinese Population Undergoing Percutaneous Coronary Intervention. Chinese Medical Journal, 2018, 131, 2699-2704.	2.3	8
48	Evaluation of the Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Bleeding Score for Predicting the Long-term Out-of-hospital Bleeding Risk in Chinese Patients after Percutaneous Coronary Intervention. Chinese Medical Journal, 2018, 131, 1406-1411.	2.3	4
49	Impact of anemia on percutaneous coronary intervention in Chinese patients: A large single center data. Journal of Interventional Cardiology, 2018, 31, 826-833.	1.2	8
50	Evaluation of CRUSADE and ACUITY-HORIZONS Scores for Predicting Long-term Out-of-Hospital Bleeding after Percutaneous Coronary Interventions. Chinese Medical Journal, 2018, 131, 262-267.	2.3	3
51	Association of Plasma Lipoprotein(a) With Long-Term Adverse Events in Patients With Chronic Kidney Disease Who Underwent Percutaneous Coronary Intervention. American Journal of Cardiology, 2018, 122, 2043-2048.	1.6	15
52	Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study. Cardiovascular Diabetology, 2018, 17, 114.	6.8	8
53	Effect of PEAR1 Genetic Variants on 1-Year Outcomes in Chinese Patients with Acute Myocardial Infarction After Percutaneous Coronary Intervention. Journal of Atherosclerosis and Thrombosis, 2018, 25, 454-459.	2.0	9
54	Prognostic Value of NT-proBNP in Stable Coronary Artery Disease in Chinese Patients after Percutaneous Coronary Intervention in the Drug-eluting Stent Era. Biomedical and Environmental Sciences, 2018, 31, 859-866.	0.2	5

#	Article	IF	CITATIONS
55	Prognostic Value of the Clinical SYNTAX Score on 2-Year Outcomes in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention. American Journal of Cardiology, 2017, 119, 1493-1499.	1.6	12
56	Effect of coronary dominance on 2â€year outcomes after percutaneous coronary intervention in patients with acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2017, 89, 549-554.	1.7	4
57	Plasma big endothelin-1 and stent thrombosis: An observational study in patients undergoing percutaneous coronary intervention in China. Thrombosis Research, 2017, 159, 5-12.	1.7	8
58	Longâ€ŧerm survival after acute myocardial infarction in patients with hypertrophic cardiomyopathy. Clinical Cardiology, 2017, 40, 26-31.	1.8	12
59	Long-term Outcomes of Primary Percutaneous Coronary Intervention with Second-generation Drug-eluting Stents in ST-elevation Myocardial Infarction Patients Caused by Very Late Stent Thrombosis. Chinese Medical Journal, 2017, 130, 929-935.	2.3	6
60	Association of α2A-Adrenergic Receptor Genetic Variants with Platelet Reactivity in Chinese Patients on Dual Antiplatelet Therapy Undergoing Percutaneous Coronary Intervention. Biomedical and Environmental Sciences, 2017, 30, 898-906.	0.2	1
61	Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. Chinese Medical Journal, 2016, 129, 2269-2274.	2.3	12
62	Costs and Benefits Associated With Transradial Versus Transfemoral Percutaneous Coronary Intervention in China. Journal of the American Heart Association, 2016, 5, .	3.7	30
63	CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention. Thrombosis Research, 2016, 147, 108-114.	1.7	10
64	Effectiveness of Alcohol Septal Ablation Versus Transaortic Extended Myectomy in Hypertrophic Cardiomyopathy with Midventricular Obstruction. Journal of Interventional Cardiology, 2016, 29, 619-627.	1.2	13
65	Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention. Thrombosis Research, 2016, 141, 28-34.	1.7	26
66	Incidence of ischemic stroke and systemic embolism in patients with hypertrophic cardiomyopathy, nonvalvular atrial fibrillation, CHA2DS2-VASc score ofÂâ‰≇ and without anticoagulant therapy. Heart and Vessels, 2016, 31, 1148-1153.	1.2	7
67	Effect of platelet receptor gene polymorphisms on outcomes in ST-elevation myocardial infarction patients after percutaneous coronary intervention. Platelets, 2016, 27, 75-79.	2.3	17
68	Effectiveness of Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy With Versus Without Extreme Septal Hypertrophy. Journal of Invasive Cardiology, 2016, 28, 99-103.	0.4	2
69	Comparing of Light Transmittance Aggregometry and Modified Thrombelastograph in Predicting Clinical Outcomes in Chinese Patients Undergoing Coronary Stenting with Clopidogrel. Chinese Medical Journal, 2015, 128, 774-779.	2.3	12
70	A Comparison of Transradial and Transfemoral Approaches for Percutaneous Coronary Intervention in Elderly Patients Based on a Propensity Score Analysis. Angiology, 2015, 66, 448-455.	1.8	8
71	Comparison of Short- and Medium-Term Clinical Outcomes between Transradial Approach and Transfemoral Approach in a High-Volume PCI Heart Center in China. PLoS ONE, 2015, 10, e0118491.	2.5	5
72	ls Being an Elderly Woman a Risk Factor for Worse Outcomes After Percutaneous Coronary Intervention? A Large Cohort Study From One Center. Angiology, 2014, 65, 596-601.	1.8	1

#	Article	IF	CITATIONS
73	Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: A meta-analysis of randomized trials. Atherosclerosis, 2014, 233, 568-578.	0.8	21
74	Relationship Between ABCB1 Polymorphisms, Thromboelastography and Risk of Bleeding Events in Clopidogrel-Treated Patients With ST-Elevation Myocardial Infarction. Thrombosis Research, 2014, 134, 970-975.	1.7	25
75	LONG-TERM OUTCOMES OF COMPLETE VERSUS INCOMPLETE REVASCULARISATION AFTER DRUG-ELUTING STENT IMPLANTATION IN PATIENTS WITH MULTIVESSEL CORONARY DISEASE. Heart, 2012, 98, E158.2-E158.	2.9	0
76	Treatment of mild–moderate calcified coronary lesions with sirolimus-eluting stent: real world data from a single center. Coronary Artery Disease, 2010, 21, 33-38.	0.7	5